A Baethmann Selected Research

LF 16-0687

1/2006	Neuroprotective effects of a postischemic treatment with a bradykinin B2 receptor antagonist in a rat model of temporary focal cerebral ischemia.
9/2002	Effects of LF 16-0687 Ms, a bradykinin B(2) receptor antagonist, on brain edema formation and tissue damage in a rat model of temporary focal cerebral ischemia.
10/2001	Role of bradykinin B2 receptors in the formation of vasogenic brain edema in rats.
1/2000	LF16-0687 a novel non-peptide bradykinin B2 receptor antagonist reduces vasogenic brain edema from a focal lesion in rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A Baethmann Research Topics

Disease

8	Brain Ischemia (Cerebral Ischemia) 01/2006 - 01/2000
8	Ischemia 01/2006 - 01/2000
6	Wounds and Injuries (Trauma) 11/2003 - 01/2000
5	Infarction (Infarctions) 01/2006 - 01/2000
4	Brain Edema (Cerebral Edema) 01/2003 - 01/2000
4	Hypothermia 11/2000 - 01/2000
3	Necrosis 11/2003 - 01/2000
3	Edema (Dropsy) 01/2003 - 01/2000
3	Traumatic Brain Injuries (Traumatic Brain Injury) 09/2002 - 01/2000
3	Acidosis 04/2002 - 01/2000
3	Cold Injury 04/2001 - 01/2000
2	Stroke (Strokes) 09/2002 - 04/2002
2	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 04/2002 - 11/2000
2	Glioma (Gliomas) 07/2000 - 03/2000
1	Cerebral Infarction 05/2005
1	Hypotension (Low Blood Pressure) 04/2002
1	Hypercapnia 04/2002
1	Brain Injuries (Brain Injury) 10/2001
1	Body Weight (Weight, Body) 04/2001
1	Craniocerebral Trauma (Head Injury) 01/2000
1	Hematoma 01/2000

Drug/Important Bio-Agent (IBA)

5	BradykininIBA 01/2003 - 01/2000
4	LF 16-0687IBA 01/2006 - 01/2000
4	Bradykinin B2 ReceptorIBA 01/2006 - 01/2000
3	pimagedine (aminoguanidine)IBA 11/2003 - 01/2000
3	Saline SolutionIBA 05/2003 - 01/2000
3	Peptides (Polypeptides)IBA 01/2003 - 01/2000
2	Neuroprotective AgentsIBA 01/2006 - 05/2005
2	MagnesiumIBA 05/2005 - 05/2003
2	salicylhydroxamic acid (SHAM)IBA 11/2003 - 04/2000
2	PlacebosIBA 11/2003 - 04/2001
2	Halothane (Fluothane)FDA Link 04/2002 - 01/2000
2	IonsIBA 03/2000 - 01/2000
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2000 - 01/2000
1	Magnesium Sulfate (Sulfate, Magnesium)FDA LinkGeneric 05/2003
1	LigandsIBA 01/2003
1	2,5-dichloro-4-bromophenol (B 2)IBA 09/2002
1	Anesthetics (Anesthetic Agents)IBA 04/2002
1	GasesIBA 04/2002
1	Chloral HydrateIBA 04/2002
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2001
1	Arginine (L-Arginine)FDA Link 04/2001
1	Methohexital (Brevital)FDA Link 11/2000
1	barbituric acid (barbiturate)IBA 11/2000
1	BarbituratesIBA 11/2000
1	AnionsIBA 07/2000
1	Sodium-Potassium-Chloride SymportersIBA 07/2000
1	Sodium-Hydrogen ExchangersIBA 07/2000
1	4,4'- Diisothiocyanostilbene- 2,2'- Disulfonic Acid (DIDS)IBA 07/2000
1	phenyl-N-tert-butylnitroneIBA 04/2000
1	Ouabain (G Strophanthin)IBA 03/2000
1	AntiportersIBA 02/2000
1	SolutionsIBA 01/2000
1	Dialysis SolutionsIBA 01/2000
1	Arachidonic Acid (Vitamin F)IBA 01/2000
1	Starch (Cornstarch)IBA 01/2000
1	AlbuminsIBA 01/2000
1	Glutamic Acid (Glutamate)FDA Link 01/2000
1	Nitric Oxide Synthase (NO Synthase)IBA 01/2000
1	B 9430IBA 01/2000
1	Fluorescein (Funduscein)FDA LinkGeneric 01/2000
1	U 101033E (U-101033E)IBA 01/2000
1	Texas redIBA 01/2000
1	SuspensionsIBA 01/2000
1	Pharmaceutical PreparationsIBA 01/2000

Therapy/Procedure

3	Therapeutics 11/2000 - 01/2000
1	Artificial Respiration (Mechanical Ventilation) 04/2002
1	Lasers (Laser) 06/2000
1	Rewarming 02/2000
1	Induced Hypothermia 02/2000
1	Trephining 01/2000